GlaxoSmithKline Intellectual Property Development Limited

GlaxoSmithKline Intellectual Property Development Limited has been granted 214 US utility patents between 2015 and 2025, placing GlaxoSmithKline Intellectual Property Development Limited at rank #1,874 across all assignees tracked by PlainPatent. This portfolio spans 37 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.9 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, GlaxoSmithKline Intellectual Property Development Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 52.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 116 grants, compared with 98 in the 2015–2019 window — a +18% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. GlaxoSmithKline Intellectual Property Development Limited's 15.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 37 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark GlaxoSmithKline Intellectual Property Development Limited against peers pursuing similar technology classes.